CommercialCoverageMedium impact
08.01.57a, Lutathera® (Lutetium Lu 177 Dotatate) (Independence Administrators)
Independence Blue Cross·Oncology, Nuclear Medicine·Pharmacy
Effective date
Jan 27, 2025
We identified it
Jun 19, 2026
Summary
Independence Administrators updated medical necessity criteria for Lutathera® (Lutetium Lu 177 Dotatate), a specialized radiopharmaceutical treatment. This change affects the requirements for coverage approval of this oncology medication effective January 27, 2025.
Action Required
By January 27, 2025: Oncology providers and billing team must review updated medical necessity criteria for Lutathera® (Lutetium Lu 177 Dotatate) coverage. Update prior authorization documentation requirements in billing system and ensure clinical documentation meets new Independence Administrators criteria before submitting claims for this radiopharmaceutical treatment.